Wednesday, 26 November 2014

Gene Therapy Drug priced at 1.1 million euro: Exclusive Investment option


Gene Therapy Drug priced at 1.1 million euro: Exclusive Investment option
27 November, 2014, Germany, USANEWSCORP

Although there are several hurdles while developing a gene therapy drug, including R&D, regulatory approval, and delay in launch, but it comes with huge investment potential with high return. Glybera, from Dutch biotech firm UniQure (QURE.O) is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag. It has created a new record for a medicine to treat a rare diseaseThe new drug treats an ultra-rare genetic disease called lipoprotein lipase deficiency (LPLD) that clogs the blood with fat. The medicine was approved in Europe two years ago but its launch was delayed to for follow-up data. The company is seeks a retail price of 53,000 euros per vial, or 43,870 euros ex-factory. Other companies are looking for it's success rate in market. The drug consists of harmless modified virus as vector for corrective gene into the body's cells. The technocrats are easily available in Germany for R&D and production. There is a huge supply of concerned labor in Germany as it is hot spot for such inventions. This business carries huge return on investment, since usually drug comes with a market monopoly with least competitors. The drawbacks are delay in regulatory approval, long invention time for new drug, long launch time, high salary to R&D staff, patent expires after few years, and country-wise coverage of patented drug.  

You can share the URL on Facebook or your Social Media Site/ blog.

Submit your News in Comment box> Join us as Journalist > News Content purchase > Corrections > Copyright > Place a Classified Ad > Sell Your Home > Sell Your Business > Commercial Real Estate Ads > Advertise with us > Recruitment & Career Ads > Franchising > Advertise Locally > Contact us >

No comments:

Post a Comment